SCHEMBL6910316

SCHEMBL6910316

CC(C)(C)c1ccc(C(=O)C=C(C(=O)c2ccc(C(=O)NC(O)CC(=O)O)cc2)c2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR35 Q9HC97 1/20 0.38
GCGR P47871 1/20 0.38
GIPR P48546 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC1 Q13547 1/20 0.37
GRIN2C Q14957 1/20 0.37
HAO1 Q9UJM8 1/20 0.36
ACE P12821 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
DEGS1 O15121 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6910178 1.00 RAB9A (0.38) RAB9AMEN1NPC1POLBBLM
SCHEMBL6915817 0.89 NPC1 (0.38) RAB9AMEN1NPC1POLBBLM
SCHEMBL6910313 0.84 GCGR (0.53) RAB9AGCGRGIPRALDH1A1HPGD
SCHEMBL2665036 0.84 GCGR (0.53) RAB9AGCGRGIPRALDH1A1HPGD
SCHEMBL6910175 0.84 GCGR (0.53) RAB9AGCGRGIPRALDH1A1HPGD
SCHEMBL6910310 0.84 GCGR (0.53) RAB9AGCGRGIPRALDH1A1HPGD
SCHEMBL2646588 0.83 GCGR (0.43) RAB9AMEN1NPC1POLBBLM
SCHEMBL2646584 0.83 GCGR (0.43) RAB9AMEN1NPC1POLBBLM
SCHEMBL6917348 0.80 TRPV1 (0.47) GCGRGIPRHDAC1HDAC3NR1H4
SCHEMBL6916491 0.78 HAO1 (0.41) RAB9AMEN1KMT2AGCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR RAB9A 3070/4885MEN1 2548/4885NPC1 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.